• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    ​Drug Use Review (DUR)

    The Office of Pharmacy Services have a number of measures in place to insure appropriate, medically necessary and safe use of medications by recipients. All pharmacy claims are reviewed individually before the drugs are dispensed (Prospective Drug Use Review or ProDUR). In addition, aggregated claims data from all recipients is analyzed to identify patterns of fraud, abuse, gross overuse, or inappropriate or medically unnecessary care (Retrospective Drug Use Review or RDUR). The Pharmacy Program is advised by the Maryland Drug Use Review Board, which meets quarterly and is made up of volunteer physicians and pharmacists. Based on their analysis of patterns of drug use among Medicaid recipients and their professional experience, the Board recommends policies, medical criteria, and programs to guide prescribers, providers and patients.​​


    Prospective Drug Use Review (​ProDUR)
    ​​The ProDUR messages indicate to the pharmacist when intervention, consultation with the prescriber, or counseling of the patient should be considered.

    Retrospective Drug Use Review (RDUR)

    As part of Retrospective Drug Use Review (RDUR), recipients are identified who may be at risk for adverse outcomes due to potential drug therapy problems, such as drug-drug interactions, overutilization, drug-disease interactions, non-adherence and therapeutic duplication. Their drug history profiles are reviewed for potential drug therapy concerns. Educational intervention letter are then sent to prescribers and pharmacy providers that are non-confrontational and designed to help providers better manage patients' drug therapy.

    The RDUR Program is also responsible for identifying patients who may be receiving excessive quantities of controlled substances. Patients can be identified who utilize multiple pharmacies, multiple prescribers, or both, and whose profiles show patterns of abuse and/or gross overuse of controlled drugs. Both providers and patients are sent intervention letters. If excessive utilization of controlled drugs is not reduced, the patient may be included in the Corrective Managed Care Program and restricted to a single pharmacy.